Fulminant toxic shock syndrome following rituximab therapy in an 11-year-old boy.
Pediatric Intensive Care and Neonatal Medicine, Paris South University Hospitals AP-HP, 78, Rue du Général Leclerc, 94275, Le Kremlin Bicêtre, France.
Nolwenn
N
Le Saché
Mickael
M
Afanetti
Kumaran
K
Deiva
Laurent
L
Chevret
Pierre
P
Tissières
D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D015703:Antigens, CD / Q000378:metabolism; D002648:Child; D006801:Humans; D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D000069283:Rituximab; D012772:Shock, Septic / Q000188:drug therapy* / Q000209:etiology* / Q000382:microbiology; D013203:Staphylococcal Infections / Q000209:etiology*; D013211:Staphylococcus aureus / Q000502:physiology
D058846:Antibodies, Monoclonal, Murine-Derived; D015703:Antigens, CD; D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors; D000069283:Rituximab; C042739:antigens, CD200